SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. announced that additional data related to fidaxomicin, the Company’s lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
SOURCE Optimer Pharmaceuticals, Inc.
CONTACT: Christina Donaghy, Corporate Communications Manager, or John D.
Prunty, Chief Financial Officer & VP Finance, both of Optimer
Pharmaceuticals, Inc., +1-858-909-0736; or Jason I. Spark, Vice President
of Porter Novelli Life Sciences, +1-619-849-6005, for Optimer
Pharmaceuticals, Inc.
Web site: http://www.optimerpharma.com/
